baber/WOPTO huggingface dataset:
Patent NZ-302555-A (NZ)
Title: Recombinant swinepox virus comprising a foreign DNA sequence inserted into the swine pox virus genomic DNA wherein the foreign DNA is inserted within the HindIII K or N fragment
Inventor: COCHRAN MARK D
IPC: C07K14/03
Filed: 1996-01-19
Abstract: A recombinant swinepox virus has a foreign DNA sequence inserted within a HindIII N fragment of the swinepox virus genomic DNA and is capable of being expressed in a swinepox virus infected host cell. A recombinant swinepox virus has a foreign DNA sequence inserted within a HindIII K fragment of the swinepox virus genomic DNA and is capable of being expressed in a swinepox virus infected host cell. The foreign DNA sequence can encode an antigenic polypeptide derived from human herpes virus, herpes simplex virus, human cytomegalovirus, Epstein-Barr virus, Varicella-Zoster virus, human influenza virus, human immunodeficiency virus, rabies virus, measles virus, hepatitis B virus, hepatitis C virus, equine influenza virus neuraminidase or hemagglutinin. The recombinant swinepox virus can further comprises a foreign DNA sequence, which encodes a detectable marker such as E. coli b-galactosidase, E. coli b-glucuronidase or the foreign DNA sequence encodes a cytokine such as chicken myelomonocytic growth factor (cMGF) or chicken interferon (cIFN). The foreign DNA sequence can be under control of a promoter such as an endogenous upstream poxvirus promoter or a heterologous upstream promoter. The recombinant swinepox virus designated S-SPV-060, S-SPV-061, S-SPV-062 or S-SPV-059 is disclosed. A vaccine thereof is useful for immunizing an animal against swinepox virus.
Patent NZ-325802-A (NZ)
Title: Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
Inventor: BOSIES ELMAR
IPC: C07D401/04
Filed: 1996-12-20
Abstract: Compounds of the above formula in which: X, Y and Z are oxygen; R1 represents a group W-V: W is a valence dash or a straight-chained or branched C1-C8 alkyl or a C2-C8 alkenyl group which is optionally once or several times substituted, V is an optionally substituted monocycle or bicycle which can contain one or several heteroatoms, or W-V is a C1-C20 alkyl group which can be interrupted by heteroatoms or one or several carbon atoms are optionally substituted; R2 and R3 represent hydrogen; R4 and R5 denote independently of each other for A-D, wherein A represents a dash alkyl, alkenyl, acyl, alkylsulfonyl, sulfonyl, alkylaminocarbonyl, aminocarbonyl, alkoxycarbonyl, oxy-carbonyl, alkylaminothiocarbonyl, aminothio-carbonyl which is optionally once or several times substituted; D represents a hydrogen, monocycle or bicycle, the monocycle or bicycle is optionally once or several times interrupted by heteroatoms and the monocycle or bicycle is once or several times substituted, or R4 and R5 together with the adjacent N atom form a ring.  Also claimed are the pharmacologically acceptable salts and prodrugs thereof, their optically active forms and the process for their production.  In addition, the pharmaceutical agents comprising these compounds which are capable of matrix metalloprotease-inhibitory action are disclosed.
Patent NZ-330784-A (NZ)
Title: Modulation of th1/th2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes
Inventor: TAM ROBERT
IPC: C07H19/16
Filed: 1997-01-21
Abstract: Ribavirin3 is administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. In particular, Ribavirin3 is used to suppress Th2-mediated T cell responses and promote Th1-mediated T cell response. In other aspects of the invention, one or more Ribavirin3 analogs are administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. The Ribavirin3 analog(s) may be used to suppress or enhance Th1 or Th2-mediated T cell responses.
Patent NZ-333311-A (NZ)
Title: Benzo[g]quinoline derivatives
Inventor: GULL PETER
IPC: C07D409/14
Filed: 1997-07-07
Abstract: These benzo[g]quinoline derivatives, which are useful as pharmaceuticals for the treatment of glaucoma and myopia, are of the formula (I) wherein A and B each are H or together form a bond; X is CH2 or CO; Y is O, S, S=O, NH, NC1-4alkyl, CH2 or O-CH2 and R is of the formula (a), (b), (c), (d), (e), (f), (g), (h) or (i).
Patent NZ-500151-A (NZ)
Title: A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
Inventor: BOYLE JEFFREY STEPHEN
IPC: C07K19/00
Filed: 1998-03-26
Abstract: Methods of enhancing the immune response to an immunogen and to compositions for use in these methods. In particular, provided are DNA molecules for use in raising immune responses to antigens. The DNA molecule includes a first sequence encoding a targeting molecule (CTLA4), a second sequence encoding the antigen or an epitope thereof, and optionally a third sequence encoding a polypeptide which promotes dimerisation or multimerisation of the product encoded by the DNA molecule.
Patent NZ-500268-A (NZ)
Title: DNA sequence coding for a mammalian glucuronyl C5-epimerase and a process for its production
Inventor: LINDAHL ULF
IPC: C12N9/90
Filed: 1998-04-17
Abstract: An isolated or recombinant DNA sequence is provided coding for a mammalian glucuronyl C5-epimerase capable of converting D-glucuronic acid to L-iduronic acid.  Recombinant expression vectors comprising such DNA sequences and functional derivatives thereof are provided.  Glucuronyl C5-epimerase may be prepared in host cells transformed with these recombinant expression vectors.
Patent NZ-504807-A (NZ)
Title: Laminate, package made therefrom, and packaging method
Inventor: MUELLER WALTER B
IPC: B65B25/06
Filed: 1998-12-01
Abstract: A  laminate generally includes: a. a multilayer,  gas- impermeable  film  capable  of  delaminating  into  a   gas- permeable  portion and a gas-impermeable portion,  the  gas- permeable  portion  in  adherence with  the  gas-impermeable portion  at  a  predetermined intra-film cohesive  strength; and  b.  a  gas-permeable film bonded to the gas-impermeable film  at a bond-strength that is greater than the intra-film cohesive   strength  between  the  gas-permeable  and   gas- impermeable  portions of the gas-impermeable film.  In  this manner,  when  the laminate is subjected to  a  delaminating force,  the  laminate delaminates within the gas-impermeable film  such  that  the  gas-permeable  portion  of  the  gas- impermeable  film remains bonded to the gas-permeable  film. A  package and method of making a package using the laminate as a lidding film are also disclosed
Patent NZ-506016-A (NZ)
Title: Interactive gaming and audiovisual transmission system
Inventor: AGASSE BERNARD
IPC: A63F13/00
Filed: 1999-02-04
Abstract: An  interactive  gaming and  audiovisual  transmission system  comprising  a  central  gaming  computer  4002   for processing  gaming data, a decoder 2020 adapted  to  receive gaming  data from the central gaming computer 4002  together with  transmitted  audiovisual  data,  the  decoder  further including  a  card  reading device for  interacting  with  a user's  bank  card in order to credit a gaming account  held by  the  central  gaming computer means  in  response  to  a transfer   of  credit  from  the  user's  bank  account   is disclosed.
Patent NZ-507092-A (NZ)
Title: Diagnostics and vaccines for mycobacterial infections specifically mycobacterium paratuberculosis acylase (mpa)
Inventor: HERMON-TAYLOR JOHN
IPC: A61K39/00
Filed: 1999-03-18
Abstract: A polypeptide comprises the sequence of SEQ ID NO:2 or a polypeptide with at least 70% amino acid identity over 30 amino acids which has mpa activity. A polynucleotide of SEQ ID NO:1 encoding the polypeptide and an antibody specific to the polypeptide are described. Also described are pharmaceutical compositions and vaccines comprising the polypeptides, polynucleotides or antibodies. The presence of a Mycobacterium avium subspecies paratuberculosis (MAP) infection in a biological sample can be detected by providing a nucleic acid probe comprising a polynucleotide of SEQ ID No:1 or an antibody which is bought into contact with the sample and hybridization is allowed to occur. The formation of any nucleic acid duplex or antibody-antigen complex in the sample is detected. The method can be used to detect inflammatory diseases including CrohnÆs disease, JohneÆs disease and sarcoidosis.
Patent NZ-513730-A (NZ)
Title: Method and apparatus determining position of a movable barrier
Inventor: SMITH ALAN DANE
IPC: D05C15/24
Filed: 2000-02-16
Abstract: A movable barrier operator (10) includes an absolute position detector (124) which provides a unique value for each position of the barrier (12) along its path of travel. The absolute position detector (142) employs multiple binary serial streams and one multiple clock stream. After the first five cycles of the clock stream, the binary streams can be decoded by a processor to produce an absolute position. Every clock edge produces a new absolute position along the path of travel.
Patent NZ-517663-A (NZ)
Title: Neurotherapeutic clavulanate composition and method
Inventor: KOPPEL GARY A
IPC: A61K31/546
Filed: 2000-08-16
Abstract: Clavulanate acid and related compounds are useful, for example, for treatment of anxiety, anti-aggressive disorders, memory impairment, and disease states characterized by glutamate abnormalities. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
Patent NZ-517905-A (NZ)
Title: Promoter modulated in the presence or absence of light for regulating expression of foreign genes in transgenic plants
Inventor: VEZINA LOUIS-PHILIPPE
IPC: C12N15/09
Filed: 2000-10-02
Abstract: Described is a promoter for regulating expression of foreign genes in transgenic organisms. The promoter comprises a promoter having the identifying characteristics of a promoter having a sequence selected from the group consisting of sequences set forth in SEQ ID NOS: 1 to 3 and functional fragments or derivatives thereof, wherein the promoter is adapted to be operationally located with respect to the foreign gene to facilitate expression of the gene.
Patent NZ-520489-A (NZ)
Title: Terminal communication system without a network
Inventor: YAMAMOTO MASAAKI
IPC: H04W84/10
Filed: 2002-04-18
Abstract: Disclosed herein is a terminal communication method, wherein a portable terminal obtains specified data from a server, a service terminal obtains from a certificate authority, a server certificate encrypted by a secret key of said certificate authority, said portable terminal obtains said server certificate from said service terminal and verifies said server certificate on the basis of a public key of said certificate authority, and said portable terminal transmits said specified data to said service terminal using local communication without a network in the case that said service terminal is authenticated on the basis of said server certificate. Portable terminal MS downloads coupon data and public key KEYP2 of IP server 20 from IP server 20. Service terminal T obtains from IP server 20, a server certificate to which a digital signature is applied by secret key KEYS2. One to one local communication by infrared radiation is performed between portable terminal MS and service terminal T. At this point, portable terminal MS decrypts a server certificate by utilizing public key KEYP2 of IP server 20. Then, portable terminal MS communicates specified data after authenticating the identity of service terminal T.
Patent NZ-523912-A (NZ)
Title: Expression of biologically active polypeptides in duckweed
Inventor: STOMP ANNE-MARIE
IPC: C12N15/09
Filed: 2001-07-26
Abstract: A method of producing biologically active á-2b-interferon in a duckweed plant culture or a duckweed nodule culture, comprising the steps of: (a) culturing within a duckweed culture medium, a duckweed plant culture or a duckweed nodule culture, wherein said duckweed plant culture or said duckweed nodule culture is stably transformed to express said biologically active á-2b-interferon, and wherein said biologically active á-2b-interferon is expressed from a nucleotide sequence comprising a coding sequence for á-2b-interferon and an operably linked coding sequence for a signal peptide that directs secretion of the á-2b-interferon into the culture medium; and (b) collecting said á-2b-interferon from the duckweed culture medium. A method of producing a biologically active human growth hormone or a monoclonal antibody in a duckweed plant culture or a duckweed nodule culture, comprising the steps of: (a) culturing within a duckweed culture medium a duckweed plant culture or a duckweed nodule culture, wherein said duckweed plant culture or said duckweed nodule culture is stably transformed to express said biologically active human growth hormone or monoclonal antibody, and wherein said growth hormone or monoclonal antibody is expressed from a nucleotide sequence comprising a coding sequence for human growth hormone or monoclonal antibody, an operably linked coding sequence for a signal peptide that directs secretion of the human growth hormone or monoclonal antibody into the culture medium, and an operably linked 5' leader sequence; and (b) collecting said human growth hormone or monoclonal antibody from the duckweed culture medium; wherein the coding sequence for said human growth hormone or monoclonal antibody comprises between 70-100% Lemna gibba-preferred codons or Lemna minor-preferred codons.
Patent NZ-524485-A (NZ)
Title: 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
Inventor: MENZENBACH BERND
IPC: A61P43/00
Filed: 2001-08-29
Abstract: Disclosed are compounds 17-Methylene steroid of formula I in which R4 is a halogen atom or a pseudohalogen, R10 is a hydrogen atom or a straight-chain or branched C1-C4 alkyl group, R20 and R20a are, independently of one another, a straight-chain or branched C1-C4 alkyl or hydroxy- C1-C4 alkyl group, or one of radicals R20 and R20a is a hydrogen atom, a straight-chain or branched C1-C4 alkyl or hydroxy- C1-C4 alkyl group, and the other radical is a halogen atom or a pseudohalogen. The compounds have an active profile with a hybrid character of such that they act as inhibitors of the 5 alpha -reductase and, at the same time, as gestagens. Said compounds are thus suited for treating medical disorders that, in men and women, are a result of an increased androgen level in certain organs and tissues. The inventive compounds combined with other hormonal substances such as estrogen, testosterone or a potent androgen are suited as contraceptives for women and men.
Patent NZ-525583-A (NZ)
Title: Fabric tensioner and method of tensioning fabric
Inventor: MILTON IAN EDWARD
IPC: E04H15/32
Filed: 2001-10-17
Abstract: A method and apparatus for tensioning fabric and particularly, but not exclusively, a method and apparatus for tensioning a fabric supported by a frame in a marquee. A tensioner (2) is provided with means (4) for mounting the tensioner to a frame (100) of a marquee and means (6, 8, 42) for connecting the mounting means to a fabric to be tensioned. The connecting means comprises a resiliently bendable elongate member (6, 8) which is resiliently connected to the mounting means and comprises means (42) for engaging the fabric so as to permit a transfer of force between the fabric and the mounting means. The tensioner thereby allows fabric to be tensioned in a convenient and rapid manner.
Patent NZ-529502-A (NZ)
Title: Metalloproteinase-disintegrin family members: SVPH DNAs and polypeptides
Inventor: CERRETTI DOUGLAS PAT
IPC: A61K48/00
Filed: 2000-01-21
Abstract: Isolated SVPH-4 nucleic acid molecules, metalloproteinase-disintegrin proteins, related vectors and polypeptides, host cells comprising and antibodies thereof are disclosed. (62) Divided out of 513597
Patent NZ-529744-A (NZ)
Title: A fire retardant floor assembly
Inventor: SAUNDERS KEVIN ALLAN
IPC: E04B1/94
Filed: 2003-11-24
Abstract: Disclosed is a fire retardant floor assembly comprising: A base structure including a plurality of parallel spaced apart joists; at least two juxtaposed quadrilateral shaped floor shaped panels, each supported by the base structure and positioned in an edge to edge juxtaposed relationship with one another, wherein at least one pair of opposed edges of each panel, at least one of which edge is in the juxtaposed relationship, spans at least one adjacent pair of joists; a capping means covering the edge to edge interface of the juxtaposed panels at the joist facing major surface side of the juxtaposed panels and extending at least between adjacent joists.
Patent NZ-530852-A (NZ)
Title: Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells
Inventor: ANDERSEN DANA C
IPC: C12N1/21
Filed: 2002-08-26
Abstract: A process for producing a functional antibody or biologically active fragment in a isolated host cell transformed with two separate translational units encoding the light and heavy chains of the antibody or the fragment. The process comprises: a) culturing the isolated host cell under suitable conditions, wherein the expression of the light chain and the heavy chain is controlled by different promoters so that the light chain and the heavy chain are expressed in a sequential fashion, thereby temporally separating the production of light and heavy chains; and b) allowing the assembly of the light and heavy chains to form the antibody or fragment.
Patent NZ-535333-A (NZ)
Title: Tumor imaging amino acid analog compounds
Inventor: GOODMAN MARK M
IPC: C07F13/00
Filed: 2003-04-24
Abstract: Disclosed herein are amino acid compounds of use in detecting and evaluating brain and body tumors. These compounds combine the advantageous properties of alpha-aminoisobutyric acid (AIB) analogs namely, their rapid uptake and prolonged retention in tumors with the properties of halogen substituents, including certain useful halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. In addition the compounds can be labelled with technetium and rhenium isotopes using known chelation complexes. The amino acid compounds disclosed herein have a high specificity for target sites when administered to a subject in vivo. Preferred amino acid compounds include [18F]FAMP, ([18F]5a) and [18F]N-MeFAMP, ([18F]5b). The disclosure further features pharmaceutical compositions comprised of an alpha-amino acid moiety attached to either a four, five or a six membered carbon-chain ring. The labelled amino acid compounds are useful as imaging agents in detecting and/or monitoring tumors in a subject by Positron Emission Tomography (PET) and Single Photon Emission Computer Tomography (SPECT).
Patent NZ-536073-A (NZ)
Title: Composition for luring and controlling arthropods comprising synthetic silicic acid and protein autolysate
Inventor: PATEL SMITA
IPC: A01N59/00
Filed: 2003-04-09
Abstract: A composition comprising protein autolysates derived from yeasts, synthetic silicic acids and active compounds directed against animal pathogens, for luring and controlling animal pathogens. The composition can be used in agriculture, horticulture, forestry, animal husbandry, animal breeding, in the protection of stored products or materials, in the hygiene sector and in the domestic field.
Patent NZ-537323-A (NZ)
Title: Helix antenna including a ground plane, cylindrical helix and a lateral spiral
Inventor: CRAGGS JOHN STANLEY
IPC: H01Q1/36
Filed: 2003-06-03
Abstract: An antenna element is disclosed which includes (a) a ground plane (106), (b) a cylindrical helix (104) having a uniform pitch where the cylindrical helix (104) is disposed above the ground plane (106). The cylindrical helix (104) is connectable to a communications apparatus at a first helix end, the first helix end being located near the ground plane (106); and (c) a lateral spiral (102) substantially centred on the axis (100) of the cylindrical helix (104) where the spiral (102) has a first end connected to a second helix end. The second helix end is the opposite end of the cylindrical helix to the first helix end, and the lateral spiral (102) thereby terminates the antenna element.
Patent NZ-537399-A (NZ)
Title: Veneer lathe and method of cutting wood block by the veneer lathe
Inventor: KOIKE MASARU
IPC: B27L5/02
Filed: 2004-12-23
Abstract: A method of cutting a wood block for production of veneer by a rotary veneer lathe is disclosed. The veneer lathe includes a knife carriage which has a veneer knife (5) mounted therein and having a cutting edge (5b), a number of rotatable peripheral drive wheels (27) disposed at a spaced interval in parallel relation to the cutting edge of the veneer knife and each having on the circumferential periphery a number of tooth-like projections (27a) pierceable into the wood block (3) adjacent to the cutting edge of the veneer knife for driving the wood block from the periphery thereof for rotation about its axis, and a guide member (6) disposed adjacent to the drive wheel for guiding veneer peeled from the wood block. According to the invention, cutting of the wood block is done at a first position of the peripheral drive wheels where the veneer peeled from the wood block and moving past said guide member (6) is pierced by the projections (27a) to such an extent that substantial splits are formed in the veneer along wood grain thereof by a force of the projections acting on the veneer, and also at a second position where the projections provide no force to the veneer moving past the guide member that causes the substantial splits in the veneer along wood grain thereof.
Patent NZ-538184-A (NZ)
Title: Crystalline solid form of (2S-5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid 1.5 hydrochloride
Inventor: HALLINAN ANN E
IPC: A61P25/00
Filed: 2003-08-22
Abstract: Disclosed is a crystal form of a compound of formula (I), being (2S,5Z)-2-amino-2-methyl-7-[(1-iminoethyl)amino]-5-heptenoic acid, 1.5 hydrochloride or a physiologically functional derivative thereof. The compound may be used in the manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which an inhibitor of nitric oxide synthase is indicated.
Patent NZ-550774-A (NZ)
Title: Selected CGRP antagonists, method for the production thereof and their use as medicaments
Inventor: MUELLER STEPHAN GEORG
IPC: A61K31/501
Filed: 2005-03-23
Abstract: Disclosed are aryl-substituted piperidine-1-carboxylate derivatives as represented by the general formula (I), wherein: A and X independently represent an oxygen or sulphur atom; D, E, G, M and Q independently of one another in each case represent a methyne group or a nitrogen atom which may be substituted as defined herein; R1 represents 1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one-3-yl, 3,4-dihydro-1H-quinazolin-2-one-3-yl, 5-phenyl-2,4-dihydro-1,2,4-triazol-3-one-2-yl, 1,3-dihydroimidazo[4,5-c]quinolin-2-one-3-yl, 1,3-dihydro-naphth[1,2-d]imidazol-2-one-3-yl, 1,3-dihydro-benzimidazol-2-one-3-yl, 4-phenyl-1,3-dihydro-imidazol-2-one-1-yl, 3,4-dihydro-1H-thieno[3,2-d]pyrimidin-2-on-3-yl or a 3,4-dihydro-1H-thieno[3,4-d]pyrimidin-2-on-3-yl group; and where the remaining substituents are as defined herein. Also disclosed is the use of a compound as defined above for preparing a pharmaceutical composition for the acute and prophylactic treatment of headaches, for the treatment of non-insulin-dependent diabetes mellitus ("NIDDM"), complex regional pain syndrome (CRPS1), cardiovascular diseases, morphine tolerance, diarrhoea caused by clostridium toxin, skin diseases, inflammatory diseases, diseases accompanied by excessive vasodilatation and resultant reduced circulation of the blood, for alleviating pain or for preventive or acute therapeutic treatment of the symptoms of menopausal hot flushes caused by vasodilatation and increased blood flow in oestrogen-deficient women and hormone-treated patients with prostate carcinoma.